Skip to content
Peptigraph home

Dihexa

HGF/c-Met nootropic. Dihexa is not FDA approved for any use.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Animal evidence, 2 of 4
StatusOff FDA Category 2 (Apr 2026)Removed from FDA Category 2 on 15 Apr 2026. WADA status unclearFull legal history

Key facts

How we verify
Class
HGF/c-Met nootropic
Also called
No common aliases
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
FDA status
Not approved
Off Category 2, 15 Apr 2026
PCAC vote
Not reviewed
not on the Jul 2026 PCAC agenda
WADA
Unclear
Not named on the 2026 list
Everything on Dihexa

Dihexa guides

DosageDoses used in published studies, with the source for each.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

Dihexa: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Any condition (no goal ledger yet)Not in our ledgerNot in our ledger5Animal evidence, 2 of 4Journal of Huntington's disease 2024, PMID 38489193

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

Common questions

Is Dihexa FDA approved?

No. Dihexa is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026.

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  3. 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  4. 4United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "dihexa" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  5. 5US compounding: Dihexa acetate was removed from FDA's 503A category 2 after the nominator withdrew; FDA announced a PCAC consultation before the end of February 2027.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  6. 6Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.Journal of Huntington's disease · 2024PMID 38489193Accessed 2 Oct 2026
  7. 7PubMed search: dihexa[tiab] OR "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide"[tiab] (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide"[tiab] OR "Nle1-angiotensin IV"[tiab] OR "angiotensin IV analog"[tiab] OR "AngIV analog"[tiab] (14 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (dihexa[tiab] OR "hepatocyte growth factor"[tiab]) AND (mimetic[tiab] OR "angiotensin IV"[tiab] OR Nle[tiab]) AND (memory[tiab] OR cognit*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026

Found an error? Report a correction.